Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?
PharmacoEconomics - Open · 2026-05 · 10 (3) · 591-591
DOI: 10.1007/s41669-026-00648-9 ↗Kurz gefasst
Korrektur in der Zeitschrift PharmacoEconomics - Open, online erschienen am 21.04.2026. Verfasst von Iago Rodríguez-Lago und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain.
- Biobizkaia Health Research Institute, Barakaldo, Spain.
- Faculty of Health Sciences, Deusto University, Bilbao, Spain.
- Fresenius Kabi España, S.A.U., Barcelona, Spain.
- Axentiva Solutions S.L., Oviedo, Spain.
- Axentiva Solutions S.L., Barcelona, Spain. fibanez@axentiva.com.
Zitieren
APA
Rodríguez-Lago, I., Peinado-Fabregat, J. I., Guigini, M., Cerezales, M., Ibáñez, F., Crespo, C., & Barreiro-de Acosta, M. (2026). Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?. PharmacoEconomics - Open, 10(3), 591-591. https://doi.org/10.1007/s41669-026-00648-9
Vancouver
Rodríguez-Lago I, Peinado-Fabregat JI, Guigini M, Cerezales M, Ibáñez F, Crespo C, et al. Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?. PharmacoEconomics - Open. 2026;10(3):591-591. doi:10.1007/s41669-026-00648-9
BibTeX
@article{RodrguezLago2026,
author = {Rodríguez-Lago, Iago and Peinado-Fabregat, José Ignacio and Guigini, Marcelo and Cerezales, Mónica and Ibáñez, Francisco and Crespo, Carlos and Barreiro-de Acosta, Manuel},
title = {Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?},
journal = {PharmacoEconomics - Open},
year = {2026},
volume = {10},
number = {3},
pages = {591--591},
doi = {10.1007/s41669-026-00648-9}
}
EUVIMED